Abstract
Tuberculous intracranial mass lesions are common in settings with high tuberculosis (TB) incidence and HIV prevalence. The diagnosis of such lesions, which include tuberculoma and tuberculous abscesses, is often presumptive and based on radiological features, supportive evidence of TB elsewhere and response to TB treatment. However, the treatment response is unpredictable, with lesions frequently enlarging paradoxically or persisting for many years despite appropriate TB treatment and corticosteroid therapy. Most international guidelines recommend a 9-12 month course of TB treatment for central nervous system TB when the infecting Mycobacterium tuberculosis (M.tb) strain is sensitive to first-line drugs. However, there is variation in opinion and practice with respect to the duration of TB treatment in patients with tuberculomas or tuberculous abscesses. A major reason for this is the lack of prospective clinical trial evidence. Some experts suggest continuing treatment until radiological resolution of enhancing lesions has been achieved, but this may unnecessarily expose patients to prolonged periods of potentially toxic drugs. It is currently unknown whether persistent radiological enhancement of intracranial tuberculomas after 9-12 months of treatment represents active disease, inflammatory response in a sterilized lesion or merely revascularization. The consequences of stopping TB treatment prior to resolution of lesional enhancement have rarely been explored. These important issues were discussed at the 3rd International Tuberculous Meningitis Consortium meeting. Most clinicians were of the opinion that continued enhancement does not necessarily represent treatment failure and that prolonged TB therapy was not warranted in patients presumably infected with M.tb strains susceptible to first-line drugs. In this manuscript we highlight current medical treatment practices, benefits and disadvantages of different TB treatment durations and the need for evidence-based guidelines regarding the treatment duration of patients with intracranial tuberculous mass lesions.
Funder
Department of Science and Technology, Republic of South Africa
Fogarty International Center
South African Medical Research Council
Wellcome Trust
National Institutes of Health
National Research Foundation, South Africa
National Research Foundation SARChI Chair in Clinical Neurosciences
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference91 articles.
1. Pathology and pathogenetic mechanisms in neurotuberculosis.;D Dastur;Radiol Clin North Am.,1995
2. Diagnosis and neurosurgical treatment of tuberculous disease of the CNS.;H Dastur;Neurosurg Rev.,1983
3. Multiple ring enhancing brain lesions on computed tomography: an Indian perspective.;R Garg;J Neurol Sci.,2008
4. Intracranial mass lesions in HIV-positive patients--the KwaZulu/Natal experience. Neuroscience AIDS Research Group.;A Bhigjee;S Afr Med J.,1999
5. Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea.;P Choe;J Korean Med Sci.,2010
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献